Atma (Sambucus) tablets №12

1 tablet contains: active substances:  Sambucus nigra D1 35.7 mg, Natrium sulfuricum D6 37.2 mg, Solanum dulcamara D6 37.2 mg, Arsenicum album D12 37.2 mg, Tartarus emeticus D12 37.2 mg;

excipients: lactose monohydrate, potato starch, magnesium stearate.

Tablets.

Round flat tablets from white to slightly greenish-brown color with possible inclusions of greenish and brownish color with a dividing line.

Complex homeopathic medicine.

The drug has a systemic therapeutic effect, which is due to the combination and mutual strengthening of the action of active components. It has a broncholytic, mucolytic, anti-inflammatory, immunomodulatory and anti-allergic effect.

The drug eliminates spasm and reduces bronchial reactivity, reduces shortness of breath, reduces the frequency and intensity of suffocation attacks. Improves the quantitative (production volume) and qualitative (physico-chemical) characteristics of sputum, promotes thinning and more effective removal of thick mucus. Restores the work of the ciliated epithelium of the bronchi.

The anti-inflammatory effect of the drug prevents damage to the bronchi and lungs by free radicals and proteases, protects the pulmonary circulation from the action of inflammatory mediators.

Reduces inflammatory infiltration and swelling of the mucous membrane, prevents sclerotic changes in the bronchi and lungs. Improves systemic immunity, normalizes the functional state of the cellular link and indicators of humoral immunity (level of IgE and CIC), and also reduces antigenic stimulation. Contributes to the stabilization of the membranes of mast cells, reduces eosinophilia.

The drug increases the effectiveness of complex treatment of bronchial asthma. Enhances the broncholytic effect of inhaled corticosteroids and β2-agonists, makes it possible to reduce the period of administration or doses of these drugs as basic therapy. In the treatment of bronchitis, including obstructive, the drug reduces the broncho-obstructive syndrome, improves the dynamics of clinical (including auscultatory symptoms, external respiratory function indicators, peak flowmetry data) and subjective manifestations. In the treatment of chronic bronchitis, including smoker’s cough, the drug facilitates expectoration, improves breathing, general condition and quality of life, prevents the development of irreversible changes in the bronchi and lungs. Provides quick elimination of the asthenic symptom complex of hypoxic and infectious genesis. Stimulates individual compensatory capabilities of the body, increases non-specific reactivity of the body to infections. Improves psychometric parameters of patients’ quality of life.

Cough of infectious, allergic or mixed origin. Acute and chronic bronchitis, including obstructive syndrome. In complex therapy of bronchial asthma. Smoker’s cough.

Hypersensitivity to any component of Atma (Sambucus) tablets.